Detalhe da pesquisa
1.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
2.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869143
3.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Int J Mol Sci
; 23(7)2022 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35408919
4.
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Int J Mol Sci
; 22(8)2021 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921561
5.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Int J Mol Sci
; 21(12)2020 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575899
6.
Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074636
7.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Int J Mol Sci
; 20(9)2019 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31083638
8.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Eur J Cancer
; 203: 114039, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598922
9.
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Tumori
; 109(5): 490-495, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609207
10.
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Eur J Cancer
; 189: 112920, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277262
11.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1247291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781174
12.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1357793, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318323
13.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201470
14.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831376
15.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509300
16.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Cancer Treat Rev
; 110: 102458, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063572
17.
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.
Front Oncol
; 12: 880008, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35692798
18.
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
Cancers (Basel)
; 14(7)2022 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406620
19.
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
Front Oncol
; 11: 689829, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195090
20.
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
Cells
; 10(12)2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943916